LegoChem Biosciences Inc (141080) - Total Liabilities

Latest as of March 2026: ₩152.41 Billion KRW ≈ $103.29 Million USD

Based on the latest financial reports, LegoChem Biosciences Inc (141080) has total liabilities worth ₩152.41 Billion KRW (≈ $103.29 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

LegoChem Biosciences Inc - Total Liabilities Trend (2014–2025)

This chart illustrates how LegoChem Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. See LegoChem Biosciences Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

LegoChem Biosciences Inc Competitors by Total Liabilities

The table below lists competitors of LegoChem Biosciences Inc ranked by their total liabilities.

Company Country Total Liabilities
China Railway Construction Heavy Industry Corp Ltd
SHG:688425
China CN¥8.48 Billion
Hefei Chipmore Technology Co. Ltd. A
SHG:688352
China CN¥2.14 Billion
Guangdong HongDa Blasting Co Ltd
SHE:002683
China CN¥16.94 Billion
Amedisys Inc
NASDAQ:AMED
USA $940.48 Million
Shanghai Suochen Information Technology Co. Ltd. A
SHG:688507
China CN¥545.11 Million
CI Financial Corp
TO:CIX
Canada CA$10.53 Billion
Xiamen Changelight
SHE:300102
China CN¥2.21 Billion
Jiangsu Huahong Technology Co Ltd
SHE:002645
China CN¥2.56 Billion

Liability Composition Analysis (2014–2025)

This chart breaks down LegoChem Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see LegoChem Biosciences Inc market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 10.12 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.33 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.23 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how LegoChem Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for LegoChem Biosciences Inc (2014–2025)

The table below shows the annual total liabilities of LegoChem Biosciences Inc from 2014 to 2025.

Year Total Liabilities Change
2025-12-31 ₩160.69 Billion
≈ $108.90 Million
+31.30%
2024-12-31 ₩122.38 Billion
≈ $82.94 Million
+196.47%
2023-12-31 ₩41.28 Billion
≈ $27.98 Million
+25.35%
2022-12-31 ₩32.93 Billion
≈ $22.32 Million
-4.43%
2021-12-31 ₩34.46 Billion
≈ $23.35 Million
+44.87%
2020-12-31 ₩23.79 Billion
≈ $16.12 Million
-14.22%
2019-12-31 ₩27.73 Billion
≈ $18.79 Million
+38.49%
2018-12-31 ₩20.02 Billion
≈ $13.57 Million
-41.17%
2017-12-31 ₩34.03 Billion
≈ $23.06 Million
+15.40%
2016-12-31 ₩29.49 Billion
≈ $19.99 Million
+16.74%
2015-12-31 ₩25.26 Billion
≈ $17.12 Million
+84.24%
2014-12-31 ₩13.71 Billion
≈ $9.29 Million
--

About LegoChem Biosciences Inc

KQ:141080 Korea Biotechnology
Market Cap
$3.32 Billion
₩4.90 Trillion KRW
Market Cap Rank
#4726 Global
#118 in Korea
Share Price
₩134600.00
Change (1 day)
+0.07%
52-Week Range
₩104200.00 - ₩213500.00
All Time High
₩213500.00
About

LigaChem Biosciences Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It also sells medical devic… Read more